{
  "drug_name": "Trimethoprim-Sulfamethoxazole",
  "drug_id": "trimethoprim_sulfamethoxazole",
  "generic_name": "trimethoprim-sulfamethoxazole",
  "brand_names": ["Bactrim", "Septra", "TMP/SMX", "Cotrimoxazole"],
  "class": "Sulfonamide + Dihydrofolate Reductase Inhibitor",
  "version": "3.0.0",
  "last_updated": "2025-10-08",

  "routes": ["PO", "IV"],
  "default_route": "PO",

  "contraindications": {
    "absolute": [
      "sulfa_allergy",
      "severe_hypersensitivity",
      "megaloblastic_anemia_from_folate_deficiency",
      "first_trimester_pregnancy"
    ],
    "relative": [
      "G6PD_deficiency",
      "severe_renal_impairment",
      "severe_hepatic_impairment"
    ],
    "note": "Avoid in pregnancy (especially 1st trimester). Contraindicated in sulfa allergy."
  },

  "allergy_considerations": {
    "sulfa_allergy": {
      "safe": false,
      "contraindicated": true,
      "note": "Absolutely contraindicated in sulfa allergy. Use doxycycline or clindamycin instead."
    },
    "pcn_allergy": {
      "safe": true,
      "note": "Safe with penicillin allergy (no cross-reactivity)"
    }
  },

  "pregnancy_category": "D",
  "pregnancy_safe": false,
  "pregnancy_notes": "Avoid in 1st trimester (neural tube defects). Avoid in 3rd trimester (kernicterus risk). Use only if benefits outweigh risks.",

  "renal_adjustment": {
    "required": true,
    "adjustments": {
      "CrCl_>30": {
        "dose": "Standard dose",
        "note": "No adjustment needed"
      },
      "CrCl_15_30": {
        "dose": "50% of standard dose",
        "note": "Reduce dose by 50%"
      },
      "CrCl_<15": {
        "dose": "Avoid or use alternative",
        "note": "Contraindicated in severe renal impairment"
      }
    }
  },

  "dosing": {
    "by_indication": {
      "ssti": {
        "dose": "1-2 DS tablets PO",
        "frequency": "BID (q12h)",
        "duration": "7-10 days",
        "note": "First-line for MRSA skin infections (outpatient)",
        "route": "PO",
        "loading_dose": null
      },
      "uti": {
        "dose": "1 DS tablet PO",
        "frequency": "BID (q12h)",
        "duration": "3-5 days (uncomplicated)",
        "note": "Avoid if local resistance >20%. Not recommended for pyelonephritis.",
        "route": "PO"
      },
      "cystitis": {
        "dose": "1 DS tablet PO",
        "frequency": "BID (q12h)",
        "duration": "3 days",
        "note": "Short course for uncomplicated cystitis in women",
        "route": "PO"
      },
      "pcp_treatment": {
        "dose": "TMP 15-20 mg/kg/day IV (divided q6-8h)",
        "frequency": "q6-8h",
        "duration": "21 days",
        "note": "Pneumocystis pneumonia treatment (HIV/AIDS)",
        "route": "IV"
      },
      "pcp_prophylaxis": {
        "dose": "1 SS tablet PO daily",
        "frequency": "daily",
        "duration": "Ongoing",
        "note": "Pneumocystis prophylaxis for HIV (CD4 <200)",
        "route": "PO"
      },
      "mrsa_ssti": {
        "dose": "1-2 DS tablets PO",
        "frequency": "BID (q12h)",
        "duration": "7-14 days",
        "note": "Excellent MRSA coverage for skin/soft tissue infections",
        "route": "PO"
      }
    },
    "pediatric": {
      "note": "TMP 8-12 mg/kg/day divided q12h (based on TMP component)"
    }
  },

  "monitoring": {
    "required": ["clinical response", "CBC (if prolonged therapy)"],
    "optional": ["renal function", "potassium (can cause hyperkalemia)"]
  },

  "drug_interactions": {
    "major": ["warfarin (increases INR)", "methotrexate", "phenytoin"],
    "moderate": ["ACE inhibitors (hyperkalemia)", "diuretics"]
  },

  "adverse_effects": {
    "common": ["nausea", "rash", "photosensitivity"],
    "serious": [
      "Stevens-Johnson syndrome",
      "toxic epidermal necrolysis",
      "hyperkalemia",
      "bone marrow suppression",
      "severe hypersensitivity"
    ],
    "rare": ["agranulocytosis", "aplastic anemia"]
  },

  "spectrum": {
    "gram_positive": "Good (including MRSA)",
    "gram_negative": "Good (E. coli, but resistance increasing)",
    "anaerobes": "Limited",
    "atypicals": "Limited"
  },

  "notes": [
    "First-line for MRSA skin/soft tissue infections (outpatient)",
    "Avoid if local UTI resistance >20%",
    "Contraindicated in sulfa allergy",
    "Avoid in pregnancy (especially 1st trimester)",
    "Can cause severe hypersensitivity reactions (SJS/TEN)",
    "Monitor for hyperkalemia (especially with ACE inhibitors)",
    "DS = Double Strength (TMP 160mg / SMX 800mg)",
    "SS = Single Strength (TMP 80mg / SMX 400mg)"
  ],

  "evidence": [
    "IDSA SSTI Guidelines 2014 - first-line for MRSA",
    "IDSA Uncomplicated UTI Guidelines 2019",
    "CDC PCP Prophylaxis Guidelines"
  ]
}
